福元医药：子公司盐酸溴己新口服溶液获得药品注册证书

Core Viewpoint - Fuyuan Pharmaceutical's subsidiary has received approval for a new oral solution, indicating a significant advancement in its product pipeline and potential market opportunities in respiratory treatments [1] Group 1: Product Approval - Fuyuan Pharmaceutical announced that its wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Bromhexine Hydrochloride Oral Solution from the National Medical Products Administration [1] - The approved drug is intended for symptomatic treatment of respiratory diseases related to mucus secretion or clearance disorders in adults, adolescents, and children aged 6 and above [1] Group 2: Financial Investment - As of the announcement date, Fuyuan has invested a total of 1.1143 million yuan (approximately 0.17 million USD) in the research and development of this drug [1]